T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: Randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 967-972

  Schaed, Susanne G ^a   Klimek, Virginia M ^a   Panageas, Katherine S ^a   Musselli, Cristina M ^a   Butterworth, Leah ^a   Hwu, Wen Jen ^a   Livingston, Philip O ^a   Williams, Linda ^a   Lewis, Jonathan J ^a   Houghton, Alan N ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; QS 21; TYROSINASE RELATED PROTEIN 1; TYROSINASE[368-376] PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MELANOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FREUND'S ADJUVANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; PEPTIDE FRAGMENTS; SAPONINS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION;

EID: 0036094530     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
2. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
3. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
4. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
5. + T cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
6. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
7. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
8. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
9. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
10. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
11. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex
12. A purified saponin acts as an adjuvant for a T-independent antigen
13. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21
14. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21
15. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine
16. + cytotoxic T lymphocyte responses
17. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
18. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing
19. Intradermal injection of granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells
20. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
21. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptide
22. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens
23. Immunological memory and protective immunity: Understanding their relation
24. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation
25. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
26. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
27. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity
28. Role of antigen-presenting cells in mediating tolerance and autoimmunity
29. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
30. Phase I trial of a MART-1 peptide vaccine in incomplete Freund's adjuvant for resected high-risk melanoma
31. Immunization of patients with melanoma peptide vaccines:Immuno-logic assessment using the ELISPOT assay